Your browser doesn't support javascript.
loading
Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant.
Francke, Klaus; Chattopadhyay, Niladri; Klein, Stefan; Rottmann, Antje; Krickau, Dennis; van de Wetering, Jeroen; Friedrich, Christian.
Afiliação
  • Francke K; Bayer AG Research and Development, Pharmaceuticals, Clinical Pharmacology 1, Building M004, Muellerstrasse 178, 13353, Berlin, Germany.
  • Chattopadhyay N; Bayer AG Research and Development, Pharmaceuticals, Clinical Pharmacology 1, Building M004, Muellerstrasse 178, 13353, Berlin, Germany.
  • Klein S; Bayer AG Research and Development, Pharmaceuticals, Clinical Pharmacology 1, Building M004, Muellerstrasse 178, 13353, Berlin, Germany.
  • Rottmann A; Bayer AG Research and Development, Pharmaceuticals, Clinical Pharmacology 1, Building M004, Muellerstrasse 178, 13353, Berlin, Germany.
  • Krickau D; Bayer AG Research and Development, Pharmaceuticals, Clinical Pharmacology 1, Building M004, Muellerstrasse 178, 13353, Berlin, Germany.
  • van de Wetering J; PRA Health Sciences, Van Swietenlaan 6, 9728 NZ, Groningen, The Netherlands.
  • Friedrich C; Bayer AG Research and Development, Pharmaceuticals, Clinical Pharmacology 1, Building M004, Muellerstrasse 178, 13353, Berlin, Germany. christian.friedrich@bayer.com.
Eur J Drug Metab Pharmacokinet ; 48(1): 75-87, 2023 Jan.
Article em En | MEDLINE | ID: mdl-36469250
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antagonistas do Receptor Purinérgico P2X Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antagonistas do Receptor Purinérgico P2X Idioma: En Ano de publicação: 2023 Tipo de documento: Article